Pfizer to advance three key oncology compounds into phase 3 trials in 2007, Company tells financial analysts

NEW YORK, JUNE 4, 2007 - Pfizer Inc announced that it is advancing key compounds through clinical development at a meeting with financial analysts today in connection with the American Society of Clinical Oncology annual meeting (ASCO) in Chicago.  The company highlighted the following oncology compounds that are currently in Phase III trials as well as additional compounds expected to advance into Phase III trials in the next year: 

Compound  Current Phase 3 Programs  New Phase 3 Programs
Breast cancer
  Non-small-cell lung,
    colorectal, and hepatocellular
    (liver) cancer
Thyroid cancer
  Pancreatic cancer
  Non-small-cell lung cancer
CP 675,206
  Data available 2008
PF 3,512,676
Non-small-cell lung
  Data available 2008

Pfizer invests more than 20 percent of its development budget in oncology research with active programs in immunotherapy, signal transduction inhibition, and angiogenesis inhibition. During the past five years, the number of R&D oncology projects in Pfizer has increased four-fold. In addition to the approximately 30 programs in preclinical development, 16 Pfizer oncology compounds are in Phase I-III clinical development including four compounds currently in phase II and three compounds, as well as a potential additional indication for Sutent, currently in phase III.

"We have had a clear and sustained focus on advancing our oncology clinical program and we are making significant progress as demonstrated by the depth and breadth of scientific presentations at ASCO," said Dr. Charles Baum, vice president of Pfizer Global Research and Development.

"We have compounds in Phase III, or nearing Phase III, which address more than 70 percent of deaths due to various cancer types. We continue to move our pipeline closer to regulatory submissions and closer to broad availability for the cancer patients that could benefit from them."

At ASCO, extensive data presentations were made concerning long-established Pfizer oncology medicines, including Camptosar and Aromasin.  More than 50 additional abstracts discussed new data on the new medicine Sutent and on nine compounds in Pfizer's broad and deep new-product pipeline in oncology.